NYSE · BLCOHealthcareOphthalmic Goods

Bausch + Lomb financials

$17.14+1.12%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
Revenue$5.10B$4.79B$4.15B$3.77B
Gross profit$3.05B$2.92B$2.50B$2.25B
Gross margin59.8%60.9%60.4%59.7%
Operating income$188.0M$206.0M$204.0M$207.0M
Net income-$360.0M-$317.0M-$260.0M$6.0M
Net margin−7.1%−6.6%−6.3%0.2%
Diluted EPS$-1.02$-0.90$-0.74$0.02
EBITDA$671.0M$724.0M$609.0M$586.0M
Operating cash flow$283.0M$232.0M-$17.0M$345.0M
Free cash flow-$66.0M-$59.0M-$198.0M$170.0M
Diluted shares353.8M351.8M350.5M350.2M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31
Cash & equivalents$383.0M$305.0M$331.0M$354.0M
Short-term investments$0.00$0.00$0.00$0.00
Total debt$5.08B$4.78B$4.56B$2.44B
Total assets$14.02B$13.47B$13.44B$11.14B
Total liabilities$7.50B$6.92B$6.52B$4.04B
Shareholders' equity$6.52B$6.54B$6.92B$7.10B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology